サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1433604

大麻医薬品の市場規模、シェア、動向分析レポート：ブランドタイプ別、地域別、セグメント予測、2024年～2030年

Cannabis Pharmaceuticals Market Size, Share & Trends Analysis Report By Brand Type (Sativex, Epidiolex, Other Brands), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
大麻医薬品の市場規模、シェア、動向分析レポート：ブランドタイプ別、地域別、セグメント予測、2024年～2030年
出版日: 2024年01月12日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

大麻医薬品市場の成長と動向：

Grand View Research, Inc.の新しいレポートによると、世界の大麻医薬品の市場規模は2030年までに115億3,000万米ドルに達する見込みです。

市場は2024年から2030年にかけてCAGR32.6％で拡大すると予想されています。睡眠障害、痛み、炎症、てんかん、食欲不振、多発性硬化症、統合失調症など、さまざまな適応症に対する大麻の用途の増加が市場成長を促進しています。医療目的の加工、定量化、パッケージ化された大麻製品に対する需要は著しく増加しています。さらに、大麻製品に対する消費者や規制当局の受け入れが増加しており、市場成長にプラスの影響を与えています。例えば、EpidiolexやSativexのような大麻ベースの製品の規制上の承認は、大麻の使用に関する患者と医師の両方の視点を改善しています。

研究開発活動や製品承認の増加は、予測期間中の市場成長を促進すると予想されます。例えば、2021年8月、GWファーマシューティカルは、英国医薬品ヘルスケア製品規制庁（MHRA）から結節性硬化症複合発作の治療にEPIDYOLEXを使用する承認を取得しました。このような承認は、製薬業界における大麻の需要を増加させると推定されます。

多発性硬化症、てんかん、慢性疼痛、がんなどのさまざまな病状を治療するために大麻医薬品を利用することの肯定的な効果を示す臨床試験の数が増加していることは、市場の成長を後押しする主な要因です。臨床試験によってもたらされたポジティブな結果は、大麻や大麻を使用して開発された医薬品に対する患者やヘルスケア専門家の見方を変えるのに役立ちます。例えば、ClinicalTrials.govが提供するデータによると、2022年現在、サティベックスに関する約722の試験がアクティブであり、募集中、募集停止、または招待による登録のいずれかが行われています。

大麻医薬品市場レポートハイライト

  • ブランドタイプ別では、エピディオレックスセグメントが2023年の世界市場で98.5%の最大売上シェアを占めました。重症てんかん、ドラベ症候群、レノックス・ガストー症候群、結節性硬化症複合体の治療薬として各国で承認が進んでいることが、セグメントの成長を支えています。
  • 欧州は、医療用大麻の使用者数の増加と、同地域における主要メーカーの存在により、2023年に最大の収益シェアを占めました。
  • 中南米市場は、予測期間中に最も速い速度で成長すると推定されます。これは、同地域における大麻医薬品の使用に対する合法化と好意的なガイドラインの拡大に起因しています。

目次

第1章 大麻医薬品市場：調査手法と範囲

第2章 大麻医薬品市場：エグゼクティブサマリー

  • 市場の見通し
  • セグメントの見通し
  • 競合考察

第3章 大麻医薬品市場：変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
  • 大麻医薬品市場分析ツール

第4章 大麻医薬品市場：ブランドタイプ別の推定・動向分析

  • ブランドタイプ別の市場シェア（2023年・2030年）
  • セグメントダッシュボード
  • ブランドタイプ別の市場見通し
  • 市場規模、予測および動向分析（2018年～2030年）

第5章 大麻医薬品市場：地域別の推定・動向分析

  • 地域別の市場シェア分析（2023年・2030年）
  • 地域別の市場ダッシュボード
  • 地域別の市場のスナップショット
  • 市場規模、予測および動向分析（2018年～2030年）
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スイス
    • チェコ共和国
    • クロアチア
    • ポーランド
    • オランダ
  • アジア太平洋
    • 日本
    • オーストラリア
    • 韓国
    • ニュージーランド
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • ウルグアイ
    • チリ
    • ペルー
  • 中東・アフリカ
    • イスラエル

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • Jazz Pharmaceuticals, Inc.
    • AbbVie, Inc.
    • Insys Therapeutics, Inc.
    • Bausch Health Companies, Inc.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 4 U.S. cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 5 Canada cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 6 Europe cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 7 Europe cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 8 Germany cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 9 UK cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 10 France cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 11 Italy cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 12 Switzerland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 13 Czech Republic cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 14 Croatia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 15 Poland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 16 Netherland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 19 Japan cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 20 South Korea cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 21 Australia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 22 New Zealand cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 23 Latin America cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 24 Latin America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 25 Brazil cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 26 Mexico cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 27 Argentina cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 28 Colombia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 29 Uruguay cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 30 Chile cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 31 Peru cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 32 MEA cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 33 MEA cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 34 Israel cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Cannabis pharmaceuticals market: market outlook
  • Fig. 9 Cannabis pharmaceuticals competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Cannabis pharmaceuticals market driver impact
  • Fig. 13 Cannabis pharmaceuticals market restraint impact
  • Fig. 14 Cannabis pharmaceuticals market: Brand type movement analysis
  • Fig. 15 Cannabis pharmaceuticals market: Brand type outlook and key takeaways
  • Fig. 16 Sativex market estimates and forecast, 2018 - 2030
  • Fig. 17 Epidiolex market estimates and forecast, 2018 - 2030
  • Fig. 18 Other brands market estimates and forecast, 2018 - 2030
  • Fig. 19 Global cannabis pharmaceuticals market: Regional movement analysis
  • Fig. 20 Global cannabis pharmaceuticals market: Regional outlook and key takeaways
  • Fig. 21 North America, by country
  • Fig. 22 North America market estimates and forecasts, 2018 - 2030
  • Fig. 23 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 24 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 25 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 26 UK market estimates and forecasts, 2018 - 2030
  • Fig. 27 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 28 France market estimates and forecasts, 2018 - 2030
  • Fig. 29 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 30 Poland market estimates and forecasts, 2018 - 2030
  • Fig. 31 Croatia market estimates and forecasts, 2018 - 2030
  • Fig. 32 Czech Republic market estimates and forecasts, 2018 - 2030
  • Fig. 33 Switzerland market estimates and forecasts, 2018 - 2030
  • Fig. 34 Netherland market estimates and forecasts, 2018 - 2030
  • Fig. 35 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 36 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 37 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 38 New Zealand market estimates and forecasts, 2018 - 2030
  • Fig. 39 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 40 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 41 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 42 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 43 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 44 Colombia market estimates and forecasts, 2018 - 2030
  • Fig. 45 Uruguay market estimates and forecasts, 2018 - 2030
  • Fig. 46 Chile market estimates and forecasts, 2018 - 2030
  • Fig. 47 Peru market estimates and forecasts, 2018 - 2030
  • Fig. 48 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 49 Israel market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-4-68038-473-4

Cannabis Pharmaceuticals Market Growth & Trends:

The global cannabis pharmaceutical market size is expected to reach USD 11.53 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 32.6% from 2024 to 2030.The rise in applications of cannabis for various indications, including sleep disorders, pain, inflammation, epilepsy, anorexia, multiple sclerosis, and schizophrenia, is driving the market growth. Demand for processed, quantified, and packaged cannabis products for medical purposes is significantly increasing. Moreover, consumer and regulatory acceptance of cannabis products is increasing, positively impacting the market growth. For instance, regulatory approval of cannabis-based products such as Epidiolex and Sativex is improving the perspectives of both patients and physicians regarding the use of cannabis.

An increasing number of research and development activities and product approvals are anticipated to drive market growth over the forecast period. For instance, in August 2021, GW Pharmaceutical received approval for using EPIDYOLEX to treat tuberous sclerosis complex seizures from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Such approvals are estimated to increase demand for cannabis in the pharmaceutical industry.

The rising number of clinical trials signifying the positive effects of utilizing cannabis pharmaceuticals for treating various medical conditions, such as multiple sclerosis, epilepsy, chronic pain, and cancer, is a major factor boosting market growth. Positive results provided by clinical trials help to change the perspective of patients & healthcare professionals toward cannabis and pharmaceutical drugs developed using cannabis. For instance, as per the data provided by ClinicalTrials.gov, as of 2022, there are around 722 studies for Sativex that are active, either recruiting, not recruiting, or enrolling by invitation.

Cannabis Pharmaceuticals Market Report Highlights:

  • By brand type, epidiolex segment held the largest revenue share of 98.5% in the global market in 2023. Growing approval of the drug for the treatment of severe forms of epilepsy, Dravet syndrome, Lennox Gastaut syndrome, and Tuberous Sclerosis Complex in various countries is supporting segment growth
  • Europe accounted for the largest revenue share in 2023, owing to growing number of medical cannabis users, along with the presence of major manufacturers in the region
  • Latin American markets are estimated to grow at the fastest rate during the forecast period. This can be attributed to growing legalization and favorable guidelines toward using cannabis pharmaceuticals in the region

Table of Contents

Chapter 1. Cannabis Pharmaceuticals Market: Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Brand Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Cannabis Pharmaceuticals Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Brand type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cannabis Pharmaceuticals Market: Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Cannabis Pharmaceuticals Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cannabis Pharmaceuticals Market: Brand Type Estimates & Trend Analysis

  • 4.1. Brand Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Cannabis Pharmaceuticals Market by Brand Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Sativex
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Epidiolex
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Brands
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cannabis Pharmaceuticals Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.5. North America
    • 5.5.1. U.S.
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework
      • 5.5.1.3. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Canada
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework
      • 5.5.2.3. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Europe
    • 5.6.1. UK
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework
      • 5.6.1.3. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Germany
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework
      • 5.6.2.3. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.3. France
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework
      • 5.6.3.3. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.4. Italy
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Regulatory framework
      • 5.6.4.3. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.5. Switzerland
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Regulatory framework
      • 5.6.5.3. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.6. Czech Republic
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Regulatory framework
      • 5.6.6.3. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.7. Croatia
      • 5.6.7.1. Key country dynamics
      • 5.6.7.2. Regulatory framework
      • 5.6.7.3. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.8. Poland
      • 5.6.8.1. Key country dynamics
      • 5.6.8.2. Regulatory framework
      • 5.6.8.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.9. Netherlands
      • 5.6.9.1. Key country dynamics
      • 5.6.9.2. Regulatory framework
      • 5.6.9.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Asia Pacific
    • 5.7.1. Japan
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework
      • 5.7.1.3. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Australia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework
      • 5.7.2.3. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. South Korea
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework
      • 5.7.3.3. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.4. New Zealand
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework
      • 5.7.4.3. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Latin America
    • 5.8.1. Brazil
      • 5.8.1.1. Key country dynamics
      • 5.8.1.2. Regulatory framework
      • 5.8.1.3. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.2. Mexico
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Regulatory framework
      • 5.8.2.3. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.3. Argentina
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Regulatory framework
      • 5.8.3.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.4. Colombia
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Regulatory framework
      • 5.8.4.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.5. Uruguay
      • 5.8.5.1. Key country dynamics
      • 5.8.5.2. Regulatory framework
      • 5.8.5.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.6. Chile
      • 5.8.6.1. Key country dynamics
      • 5.8.6.2. Regulatory framework
      • 5.8.6.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.7. Peru
      • 5.8.7.1. Key country dynamics
      • 5.8.7.2. Regulatory framework
      • 5.8.7.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. MEA
    • 5.9.1. Israel
      • 5.9.1.1. Key country dynamics
      • 5.9.1.2. Regulatory framework
      • 5.9.1.3. South Africa market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Jazz Pharmaceuticals, Inc.
      • 6.3.1.1. Company overview
      • 6.3.1.2. Financial performance
      • 6.3.1.3. Product benchmarking
      • 6.3.1.4. Strategic initiatives
    • 6.3.2. AbbVie, Inc.
      • 6.3.2.1. Company overview
      • 6.3.2.2. Financial performance
      • 6.3.2.3. Product benchmarking
      • 6.3.2.4. Strategic initiatives
    • 6.3.3. Insys Therapeutics, Inc.
      • 6.3.3.1. Company overview
      • 6.3.3.2. Financial performance
      • 6.3.3.3. Product benchmarking
      • 6.3.3.4. Strategic initiatives
    • 6.3.4. Bausch Health Companies, Inc.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives